Your browser doesn't support javascript.
loading
Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations.
Wang, Jing; Fu, Wenjing; Bao, Wenqiang; Gong, Wenyu; Xu, Shiyun; Ling, Chun; Jin, Qichuan; Zhang, Qiguo.
Afiliação
  • Wang J; Department of Oncology and Hematology, Yizheng Hospital of Nanjing Drum Tower Hospital Group, Yizheng, PR China.
  • Fu W; Department of Hematology, Nanjing Drum Tower Hospital Clinical College, Nanjing Medical University, Nanjing, Jiangsu, PR China.
  • Bao W; Department of Hematology, Nanjing Drum Tower Hospital Clinical College, Nanjing Medical University, Nanjing, Jiangsu, PR China.
  • Gong W; Department of Hematology, The First People's Hospital of Chuzhou, Chuzhou Hospital affiliated to Anhui Medical University, Chuzhou, PR China.
  • Xu S; Department of Hematology, The First People's Hospital of Chuzhou, Chuzhou Hospital affiliated to Anhui Medical University, Chuzhou, PR China.
  • Ling C; Department of Hematology, The First People's Hospital of Chuzhou, Chuzhou Hospital affiliated to Anhui Medical University, Chuzhou, PR China.
  • Jin Q; Department of Hematology, The First People's Hospital of Chuzhou, Chuzhou Hospital affiliated to Anhui Medical University, Chuzhou, PR China.
  • Zhang Q; Department of Hematology, The First People's Hospital of Chuzhou, Chuzhou Hospital affiliated to Anhui Medical University, Chuzhou, PR China.
Platelets ; 34(1): 2176167, 2023 Dec.
Article em En | MEDLINE | ID: mdl-36786035
ABSTRACT
Essential thrombocythemia (ET) with double driver mutations is a rare disease. ET patients with both MPL and Type 1 CALR mutations have been reported. Here, we report the first case of an ET patient with both MPL S204P and Type 2 CALR mutations and a summary of our literature review findings. In the patient whose case is reported here, the disease progressed to an accelerated phase 3.5 months after diagnosis. CALR mutation disappeared and new mutations emerged as the disease progressed, such as ASXL1, CBL, ETV6, and PTPN11 mutations. This case highlights that screening for additional mutations using NGS should be considered in patients with ET to assess the prognosis, especially as the disease progresses.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trombocitemia Essencial / Transtornos Mieloproliferativos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trombocitemia Essencial / Transtornos Mieloproliferativos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article